The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
The GSK-3 Family as Therapeutic Target for Myocardial Diseases
Open accessAbstract
Glycogen synthase kinase-3 (GSK-3) is one of the few signaling molecules that regulate a truly astonishing number of critical intracellular signaling pathways. It has been implicated in several diseases including heart failure, bipolar disorder, diabetes mellitus, Alzheimer disease, aging, inflammation, and cancer. Furthermore, a recent clinical trial has validated the feasibility of targeting GSK-3 with small molecule inhibitors for human diseases. In the current review, we will focus on its expanding role in the heart, concentrating primarily on recent studies that have used cardiomyocyte- and fibroblast-specific conditional gene deletion in mouse models. We will highlight the role of the GSK-3 isoforms in various pathological conditions including myocardial aging, ischemic injury, myocardial fibrosis, and cardiomyocyte proliferation. We will discuss our recent findings that deletion of GSK-3α specifically in cardiomyocytes attenuates ventricular remodeling and cardiac dysfunction after myocardial infarction by limiting scar expansion and promoting cardiomyocyte proliferation. The recent emergence of GSK-3β as a regulator of myocardial fibrosis will also be discussed. We will review our recent findings that specific deletion of GSK-3β in cardiac fibroblasts leads to fibrogenesis, left ventricular dysfunction, and excessive scarring in the ischemic heart. Finally, we will examine the underlying mechanisms that drive the aberrant myocardial fibrosis in the models in which GSK-3β is specifically deleted in cardiac fibroblasts. We will summarize these recent results and offer explanations, whenever possible, and hypotheses when not. For these studies we will rely heavily on our models and those of others to reconcile some of the apparent inconsistencies in the literature.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
López-Otín, C., Blasco, M. A., Partridge, L., Serrano, M., & Kroemer, G. (2013) · Cell · doi:10.1016/j.cell.2013.05.039 · Cited by 14,982
Evidence for Cardiomyocyte Renewal in Humans
Bergmann, O., Bhardwaj, R. D., Bernard, S., Zdunek, S., Barnabé-Heider, F., Walsh, S., Zupicich, J., Alkass, K., Buchholz, B. A., Druid, H., et al. (2009) · Science · doi:10.1126/science.1164680 · Cited by 3,130
Transient Regenerative Potential of the Neonatal Mouse Heart
Porrello, E. R., Mahmoud, A. I., Simpson, E., Hill, J. A., Richardson, J. A., Olson, E. N., & Sadek, H. A. (2011) · Science · doi:10.1126/science.1200708 · Cited by 2,545
Targeting the TGFβ signalling pathway in disease
Akhurst, R. J., & Hata, A. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3810 · Cited by 1,466
Molecular cloning and expression of glycogen synthase kinase‐3/factor A.
Woodgett, J. R. (1990) · The EMBO Journal · doi:10.1002/j.1460-2075.1990.tb07419.x · Cited by 1,362
Self-citationActivation of canonical Wnt signalling is required for TGF-β-mediated fibrosis
Akhmetshina, A., Palumbo, K., Dees, C., Bergmann, C., Venalis, P., Zerr, P., Horn, A., Kireva, T., Beyer, C., Zwerina, J., et al. (2012) · Nature Communications · doi:10.1038/ncomms1734 · Cited by 843 · cited 1×
“Subsequently it was shown that βcatenin is a central mediator of profibrotic signaling in systemic sclerosis.(67,71) Using a tamoxifen-inducible model, Duan et al(57) demonstrated that deletion of β-catenin in fibroblasts leads to impaired fibrogenic responses and decreased cardiac performance in an I/R model.”
BackgroundLinking functional decline of telomeres, mitochondria and stem cells during ageing
Sahin, E., & DePinho, R. A. (2010) · Nature · doi:10.1038/nature08982 · Cited by 759 · cited 1×
“Genetic, epigenetic, and external factors such as dietary intake and intrinsic stresses such as reactive oxygen species are known key drivers of aging.(35) Understanding of the aging process has been hampered by several issues such as gradual and heterogeneous inception in the body, diverse phenotypes, and most import…”
BackgroundPhosphorylation by p38 MAPK as an Alternative Pathway for GSK3β Inactivation
Thornton, T. M., Pedraza-Alva, G., Deng, B., Wood, C. D., Aronshtam, A., Clements, J. L., Sabio, G., Davis, R. J., Matthews, D. E., Doble, B., et al. (2008) · Science · doi:10.1126/science.1156037 · Cited by 484 · cited 2×
“p38 MAPK (mitogen-activated protein kinase) can also inactivate GSK-3β via phosphorylation within its C-terminal region at Ser389 and Thr390.(5) The role of S21 and S9 phosphorylation in myocardial pathophysiology has been studied extensively; however, the physiological significance of tyrosine phosphorylation and p38…”
BackgroundDifferential Roles of GSK-3β During Myocardial Ischemia and Ischemia/Reperfusion
Zhai, P., Sciarretta, S., Galeotti, J., Volpe, M., & Sadoshima, J. (2011) · Circulation Research · doi:10.1161/circresaha.111.249532 · Cited by 218 · cited 2×
“Changes in autophagy contribute to the differential effects of GSK-3β on myocardial injury during prolonged ischemia and I/R.27 Taken together, the available literature suggests that GSK-3β–mediated regulation of ventricular function in ischemic heart is complex and context dependent, as overexpression/activation is d…”
Backgroundβ-catenin is a central mediator of pro-fibrotic Wnt signaling in systemic sclerosis
Beyer, C., Schramm, A., Akhmetshina, A., Dees, C., Kireva, T., Gelse, K., Sonnylal, S., de Crombrugghe, B., Taketo, M. M., Distler, O., et al. (2012) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2011-200568 · Cited by 203 · cited 1×
“Subsequently it was shown that βcatenin is a central mediator of profibrotic signaling in systemic sclerosis.(67,71) Using a tamoxifen-inducible model, Duan et al(57) demonstrated that deletion of β-catenin in fibroblasts leads to impaired fibrogenic responses and decreased cardiac performance in an I/R model.”
Backgroundβ-catenin signaling: a novel mediator of fibrosis and potential therapeutic target
Lam, A. P., & Gottardi, C. J. (2011) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e32834b3309 · Cited by 191
Cited by
Tham, Y. K., Bernardo, B. C., Ooi, J. Y. Y., Weeks, K. L., & McMullen, J. R. (2015) · Archives of Toxicology · doi:10.1007/s00204-015-1477-x · Cited by 708
Aging and Autophagy in the Heart
Shirakabe, A., Ikeda, Y., Sciarretta, S., Zablocki, D. K., & Sadoshima, J. (2016) · Circulation Research · doi:10.1161/circresaha.116.307474 · Cited by 441
Activators and inhibitors of NRF2: a review of their potential for clinical development
Robledinos-Antón, N., Fernández-Ginés, R., Manda, G., & Cuadrado, A. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/9372182 · Cited by 413
WNT Signaling in Cardiac and Vascular Disease
Foulquier, S., Daskalopoulos, E. P., Lluri, G., Hermans, K. C. M., Deb, A., & Blankesteijn, W. M. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.013896 · Cited by 347
Electrical and mechanical stimulation of cardiac cells and tissue constructs
Stoppel, W. L., Kaplan, D. L., & Black, L. D. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.07.009 · Cited by 289
Metadata
- Authors
- Lal, H., Ahmad, F., Woodgett, J., & Force, T.
- Venue
- Circulation Research
- Published
- 2015-01-02
- Volume
- 116
- Issue
- 1
- Pages
- 138-149
- ISSN
- 0009-7330 (ISSN-L)
- 1524-4571
- OpenAlex
- W2147553923
- Cited by
- 206
- References
- 11
- FWCI
- 8.63
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.